Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab

Skye Bioscience, Inc.

Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.
Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.
Agreement includes customary termination rights, reps, warranties, and indemnification.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Skye Bioscience, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at milestone payments tied to achievement of certain development and commercialization milestone events (effective 2025-12-18).

Action: entry
Agreement: license
Counterparty: Halozyme, Inc.
Value: milestone payments tied to achievement of certain development and commercialization milestone events
Effective: 2025-12-18

Exact text from the filing

On December 18, 2025, Skye Bioscience, Inc. (the “Company”) entered into a Non-exclusive Collaboration and License Agreement (the “Agreement”) with Halozyme, Inc. (“Halozyme”).

View on SEC.gov

Browse all material agreements →

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-058729

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.